Enrolment in a trial investigating a novel gene editing therapy in patients with heterozygous familial hypercholesterolemia (HeFH) has been paused after laboratory abnormalities, including a grade 3 transient increase in alanine aminotransferase (ALT), were detected in one participant. The open-label Heart-1 phase 1b clinical trial is testing the safety and tolerability of VERVE-101…
